Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, and chemotherapy is a key treatment for advanced PDAC. Gemcitabine chemotherapy is still an important component of treatment; however, there is no routine biomarker to predict its efficacy. Predictive tests may help clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Piquemal, David, Bruno, Roman, Bournet, Barbara, Ghiringhelli, Francois, Noguier, Florian, Canivet, Cindy, Bertaut, Aurélie, Pierrat, Fabien, Evesque, Ludovic, Gamez, Amelia, Cros, Jerome, Rederstorff, Emilie, Petit, Erwan, Adnet, Johan, Saint, Angélique, Drouillard, Antoine, Kempf, Emmanuelle, Soularue, Emilie, Vincent, Julie, Baumgaertner, Isabelle, Hennequin, Audrey, Tournigand, Christophe, Lopez Trabada Ataz, Daniel, Bengrine, Leila, Lepage, Come, Manfredi, Sylvain, Afchain, Pauline, Trouilloud, Isabelle, Gagnaire, Alice, LoConte, Noelle K., Bachet, Jean-Baptiste
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186541/
https://www.ncbi.nlm.nih.gov/pubmed/37201091
http://dx.doi.org/10.21037/jgo-22-946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186541/
https://www.ncbi.nlm.nih.gov/pubmed/37201091
http://dx.doi.org/10.21037/jgo-22-946

Ejemplares similares